Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.62 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.52 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.46 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.46 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 4/20 | 0.45 |
| ▸ | IDH1 | O75874 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1464367 | 0.92 | CNR2 (0.74) | CNR2P2RX1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1465504 | 0.87 | CNR2 (0.58) | CNR2CNR1IDH1MEN1KMT2A | |
| SCHEMBL1463959 | 0.83 | CNR2 (0.82) | CNR2P2RX1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL1464988 | 0.81 | CNR2 (0.70) | CNR2P2RX1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12635970 | 0.78 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL1464492 | 0.77 | CNR2 (1.00) | CNR2P2RX1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1464777 | 0.76 | MEN1 (0.49) | CNR2CNR1HDAC8HDAC6MEN1 | |
| SCHEMBL1464633 | 0.76 | CNR2 (0.79) | CNR2CYP3A4CNR1MEN1KMT2A | |
| SCHEMBL1464464 | 0.75 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL1464368 | 0.74 | CNR2 (0.76) | CNR2CNR1IDH1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | claimed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| EP-2081905-A2 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008014199-A2 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885P2RX1 66/4885KCNJ6 450/4885 |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885P2RX1 75/4885KCNJ6 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.